The Edmonton, Alberta-based company also revealed a negative adjusted EBITDA of CA$24 million, which compares to a loss of CA$49.6 million in the same period of the prior year.
Balsky said the company’s leadership in the medical business should not be overlooked and pointed out the importance of the adult-use market as well.